78 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 78 of 78 clinical reviews.
Flibanserin (Addyi) has no FDA-approved adolescent dosing. Learn why no pediatric indication exists, what the adult approval covers, and how HSDD is managed in teens.
Current Addyi (flibanserin) pricing in Ohio for 2026, including cash-pay costs, Ohio Medicaid coverage status, compounded alternatives, insurance options, and savings programs.
What Addyi (flibanserin) costs in Tennessee in 2026, including cash prices, insurance coverage, Medicaid status, compounded alternatives, telehealth access, and discount programs.
Evidence-based guide to flibanserin (Addyi) dosing in patients with renal impairment, including pharmacokinetic data, FDA labeling, clinical trial evidence, and practical prescribing considerations.
Is flibanserin (Addyi) safe during pregnancy or breastfeeding? A clinician-grade review of FDA labeling, animal reproductive data, lactation pharmacokinetics, and practical guidance for HSDD management in the peripartum period.
A guide to flibanserin (Addyi) food and supplement interactions, including alcohol, grapefruit, CYP3A4 inhibitors, and herbal products that alter drug levels.
Evidence-based guide to flibanserin use in special populations including organ transplant recipients, women living with HIV, those with hepatic impairment, and other complex clinical scenarios.
Evidence-based guidance on what to do if you miss a dose of flibanserin (Addyi), including timing rules, safety precautions, and how skipping doses affects efficacy.
A clinical guide to monitoring flibanserin (Addyi) in premenopausal adults aged 30 to 49, covering liver function, blood pressure, alcohol screening, CNS depression risk, and CYP3A4 drug interactions.
Evidence-based monitoring guide for flibanserin (Addyi) in adults aged 50-64, covering baseline labs, blood pressure checks, drug interactions, and safety signals specific to this age group.
Evidence-based monitoring guide for flibanserin (Addyi) in young adults aged 18 to 29, covering baseline labs, follow-up schedules, side-effect tracking, and special considerations for premenopausal women.
Clinical guide to flibanserin (Addyi) overdose management, including symptoms of excess dosing, pharmacologic mechanisms, emergency treatment protocols, and prevention strategies backed by FDA labeling and trial data.
A clinician-level review of flibanserin (Addyi) regulatory approvals and rejections across the US, EU, Canada, and UK, including trial data, REMS requirements, and prescribing restrictions.
Flibanserin (Addyi) has no FDA approval, clinical trial data, or guideline support for adolescent use. This article explains the safety concerns, regulatory status, and evidence gaps for ages 12 to 17.
A clinical review of flibanserin (Addyi) safety data for premenopausal women aged 30 to 49, covering side effects, drug interactions, alcohol warnings, and monitoring recommendations.
A guide to flibanserin (Addyi) safety for adults aged 50, 64, covering drug interactions, cardiovascular risk, hypotension, alcohol restrictions, and perimenopause considerations.
A guide to flibanserin (Addyi) safety for women ages 18 to 29, covering the alcohol interaction, CNS effects, fertility considerations, and the BEGONIA trial data.
A detailed review of flibanserin (Addyi) safety signals, FDA rejections, REMS requirements, alcohol interaction warnings, and post-marketing surveillance data for HSDD treatment.
A clinical history of flibanserin (Addyi), from its origins as a failed antidepressant to its FDA approval for hypoactive sexual desire disorder in premenopausal women, including mechanism of action, key trials, and regulatory timeline.
Complete clinical guide to flibanserin (Addyi) dosing for adult women aged 30-49, including the standard 100 mg bedtime dose, alcohol restrictions, drug interactions, and what to expect from treatment.
A complete 2026 guide to flibanserin (Addyi) costs in Arizona, covering cash-pay prices, Arizona Medicaid status, insurance coverage, compounded flibanserin legality, telehealth access, and savings programs.
The complete 2026 guide to flibanserin (Addyi) cost in Connecticut. Covers cash price, CT Medicaid coverage with prior authorization, compounded flibanserin via 503A pharmacies, telehealth prescribing, and savings card programs.
Full breakdown of flibanserin (Addyi) pricing in Florida for 2026, including cash-pay rates, insurance coverage, Florida Medicaid status, compounded flibanserin legality, and savings programs available to Florida residents.
Complete 2026 guide to Addyi (flibanserin) cost in Kansas, including cash-pay prices, Medicaid coverage status, 503A compounding legality, telehealth access, and savings programs.
Complete 2026 guide to Addyi (flibanserin) cost in Kentucky. Cash price, Medicaid coverage status, compounded flibanserin legality, telehealth access, and savings options explained with data.
Everything Massachusetts residents need to know about flibanserin (Addyi) costs in 2026, including Medicaid coverage, 503A compounding, telehealth access, and savings programs.
Complete 2026 guide to flibanserin (Addyi) pricing in Michigan, including cash-pay costs, Medicaid coverage with prior authorization, compounded flibanserin via 503A pharmacies, telehealth access, and manufacturer savings programs.
Complete 2026 guide to flibanserin (Addyi) costs in Missouri. Covers retail prices, Missouri Medicaid status, 503A compounded flibanserin, telehealth access, and every available savings program.
Exact Addyi (flibanserin) prices in New Hampshire for 2026, including cash-pay rates, Medicaid status, compounded flibanserin options, telehealth access, and how to use the Sprout savings card.
A complete 2026 guide to Addyi (flibanserin) costs in New Jersey, including retail prices, Medicaid coverage with prior authorization, compounded flibanserin via 503A pharmacies, insurance coverage, and manufacturer savings cards.
What is established about flibanserin (Addyi) coverage and access in New York, what pricing and formulary details require current verification, and how to check them before assuming a number is still accurate.
Addyi (flibanserin) costs $880/month cash-pay in North Carolina in 2026. Learn about NC Medicaid coverage, 503A compounded flibanserin legality, telehealth access, and manufacturer savings cards that can cut your out-of-pocket cost to near zero.
Complete 2026 guide to flibanserin (Addyi) cost in Oregon: cash price, Oregon Medicaid coverage, compounded flibanserin via 503A pharmacies, telehealth access, and manufacturer savings programs.
A guide to flibanserin (Addyi) pricing in Texas for 2026, covering cash pay, insurance coverage, Texas Medicaid rules, compounded alternatives, telehealth access, and savings programs.
Complete 2026 guide to flibanserin (Addyi) cost in Washington state: retail price, Medicaid coverage with PA, 503A compounding, telehealth access, and every savings option available.
A clinical breakdown of flibanserin (Addyi) pricing, generic availability, and how it compares in cost and efficacy to bremelanotide (Vyleesi) and off-label alternatives for HSDD.
A clinical review of flibanserin (Addyi) pipeline developments, new delivery systems under investigation, and the future of HSDD pharmacotherapy for premenopausal women.
A comprehensive clinical guide to flibanserin (Addyi) dosing in women aged 65 and older, covering pharmacokinetics, fall risk, drug interactions, and the FDA label's geriatric-use statement.
A clinician-grade guide to monitoring flibanserin (Addyi) in women aged 65 and older, covering falls risk, CNS depression, renal function, drug interactions, and when to consider deprescribing.
A guide to flibanserin (Addyi) safety in women aged 65 and older, covering falls risk, drug interactions, renal function, and deprescribing considerations backed by clinical evidence.
A clinical deep-dive into flibanserin (Addyi) manufacturing, supply chain history, shortage events, mechanism of action, and what prescribers and patients need to know in 2024.
A physician-level breakdown of how flibanserin (Addyi) works, covering its serotonin, dopamine, and norepinephrine receptor pharmacology, the BEGONIA trial data, and what the neuroscience means for clinical practice.
Evidence-based monitoring schedule for flibanserin (Addyi), including baseline labs, liver function testing, blood pressure checks, and follow-up exam intervals.
A clinical breakdown of flibanserin (Addyi) patent status, regulatory exclusivity, generic approval pathway, and projected availability dates for generic versions.
Complete pharmacokinetic profile of flibanserin (Addyi) including absorption, distribution, CYP3A4 metabolism, elimination half-life, food effects, and clinical implications for HSDD treatment.
A clinical review of flibanserin (Addyi) real-world evidence from registries, post-market surveillance, and observational studies, including mechanism of action and effectiveness outside clinical trials.
Complete guide to flibanserin (Addyi) storage conditions, shelf life, stability data, and mechanism of action. with FDA and PubMed citations.
Complete guide to flibanserin (Addyi) dosing for women aged 18 to 29, covering the 100 mg bedtime dose, alcohol restrictions, drug interactions, REMS requirements, and fertility and family-planning considerations for young adult patients.
A complete guide to Aetna CVS Health coverage for Addyi (flibanserin), including prior authorization criteria, step therapy requirements, appeal strategy, and cost-saving options for premenopausal women with HSDD.
A clinical and coverage guide to Anthem (Elevance Health) prior authorization, step therapy, formulary tier, and appeal pathways for Addyi (flibanserin) for HSDD in premenopausal women.
A clinical and insurance guide covering BCBS Federated formulary status, prior authorization criteria, step therapy, appeals, and out-of-pocket cost options for Addyi (flibanserin) in premenopausal women with HSDD.
A complete guide to Cigna coverage for Addyi (flibanserin): formulary tier, prior-authorization criteria, step therapy, appeal process, and manufacturer savings options.
A clinical guide to Humana coverage of Addyi (flibanserin) for HSDD: formulary tiers, prior authorization requirements, step therapy, appeal pathways, and out-of-pocket cost options.
A detailed guide to Kaiser Permanente's coverage policy, prior-authorization requirements, formulary tier, step-therapy rules, and appeal process for Addyi (flibanserin) for HSDD.
A detailed look at Medicare Advantage coverage policies for Addyi (flibanserin), including prior authorization criteria, step therapy requirements, formulary status, appeal rights, and cash-pay alternatives for premenopausal women with HSDD.
A state-by-state guide to Medicaid coverage of flibanserin (Addyi) for HSDD: formulary status, prior authorization criteria, step therapy requirements, appeal rights, and cost alternatives.
Find out whether TRICARE covers Addyi (flibanserin) for HSDD, what prior-authorization criteria apply, how step therapy works, and exactly how to appeal a denial. prepared by the HealthRX.com Editorial Team.
A guide to UnitedHealthcare coverage for Addyi (flibanserin), including prior authorization criteria, step therapy requirements, formulary tier placement, appeals, and cost-saving strategies for HSDD treatment.
A clinician-grade guide to every major flibanserin (Addyi) drug interaction, including CYP3A4 inhibitors, alcohol, CNS depressants, hormonal contraceptives, and P-gp substrates, with FDA and PubMed citations.
Flibanserin is contraindicated in all degrees of hepatic impairment due to a 4.5-fold increase in drug exposure. Learn the pharmacokinetic data, FDA warnings, and clinical alternatives.
Showing the first 60 matches. Use search or filters to narrow the library.